loading page

DINUTUXIMAB BETA RELATED SEVERE NEUROTOXICITY: RESOLUTION WITH THE USE OF PLASMAPHERESIS
  • +3
  • Vassilios Papadakis,
  • Charikleia Kelaidi,
  • Kalliopi Zisaki,
  • Kondilia Antoniadi,
  • Georgios Pitsoulakis,
  • Sophia Polychronopoulou
Vassilios Papadakis
Agia Sofia Children's Hospital

Corresponding Author:vpapadak@otenet.gr

Author Profile
Charikleia Kelaidi
Agia Sofia Children's Hospital
Author Profile
Kalliopi Zisaki
Agia Sofia Children's Hospital
Author Profile
Kondilia Antoniadi
Agia Sofia Children's Hospital
Author Profile
Georgios Pitsoulakis
Agia Sofia Children's Hospital
Author Profile
Sophia Polychronopoulou
Agia Sofia Children's Hospital
Author Profile

Abstract

Survival of high risk neuroblastoma patients is increased with the use of dinutuximab beta (DB). This anti-ganglioside 2 antibody promotes neuroblastoma cell killing but has on-target off-tumor nervous system side effects. A patient with high-risk neuroblastoma treated with DB and cis-retinoic acid without interleukin-2 presented with severe encephalopathy. Prompt commencement of acyclovir, steroids and intravenous immunoglobulin infusions proved unsuccessful. Symptomatic improvement concurred with the initiation of high-dose steroid pulses and serial plasmapheresis sessions. Timely management of severe DB neurotoxicity as immune-based encephalomyelitis and prompt initiation of plasmapheresis, if needed, can reverse symptoms and offer long-term recovery of the patients.